A comprehensive mini-review published today after peer review in Brain Medicine by Dr. Tao Ma and colleagues at Wake Forest University School of Medicine synthesizes emerging evidence that two ...

BUFFALO, NY- March 7, 2023 – Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) published a new research paper in Volume 15, Issue 4, entitled, “Isoform-specific ...

Dr. Tao Ma and colleagues synthesize emerging evidence on AMPKα isoforms, proposing isoform-specific targeting as a novel therapeutic strategy for Alzheimer's disease and related dementias ...

LEHI, Utah, Oct. 29, 2024 /PRNewswire/ -- Biolexis Therapeutics, a pioneering biopharmaceutical company focused on developing next-generation weight loss treatments, today announced the successful ...

The AMP-activated protein kinase (AMPK) is involved in the control of food intake by the hypothalamus. The aim of this work was to investigate if modification of hypothalamic AMPK regulation could be ...

Researchers have developed a new system that lets them study in more detail than ever exactly how, where and when the metabolic protein AMPK carries out its molecular and therapeutic functions. The ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, ...

LEHI, Utah, June 12, 2025 /PRNewswire/ -- Biolexis Therapeutics, Inc. (www.biolexistx.com), a clinical-stage therapeutics company pioneering next-generation treatments for metabolic and muscle-wasting ...

In preclinical studies, Biolexis' oral GLP-1 receptor agonist, BLX-7006, resulted in a 29% reduction in weight in diet induced obesity mice. In GLP toxicology studies, BLX-7006 demonstrated no ...